Annual Report 2024
Division of Rare Cancer Research
Tadashi Kondo, Rei Noguchi
Introduction
In the field of rare cancer research, we conduct fundamental studies aimed at generating findings that will truly benefit clinical care for patients with rare cancers. Our goal is to achieve discoveries that, one day, patients, healthcare professionals, and people around the world will look back on and say, “I’m glad this research was done.”
The Team and What We Do
To advance research in rare cancers, we established patient-derived cancer models, conducted drug sensitivity assays, and performed proteogenomic analyses to comprehensively investigate genomic and proteomic alterations. In addition, to address the question of “Why are rare cancers rare?”, we initiated comparative oncology studies. The outcomes of these research activities have been presented in peer-reviewed publications and at national and international scientific conferences.
Research Activities
A postdoctoral researcher was trained in translational research, and graduate students from Chiba University and Nagasaki University, as well as students from the Tokyo College of Biotechnology, were educated in cancer research.
Future Prospects
Establishment and application of research platforms for rare cancers, comprehensive analyses for the molecular backgrounds of carcinogenesis and disease progression, and cross-species understanding of mechanisms of tumorigenesis through comparative oncology will ultimately lead to an improvement in treatment outcomes for patients with rare cancers.
List of papers published in 2024
Journal
1. Noguchi R, Yamaguchi K, Yano H, Gohda Y, Kiyomatsu T, Ota Y, Igari T, Takahashi N, Ohsugi T, Takane K, Ikenoue T, Niida A, Shimizu E, Yamaguchi R, Miyano S, Imoto S, Furukawa Y. Cell of origin and expression profiles of pseudomyxoma peritonei derived from the appendix. Pathology, research and practice, 266:155776, 2025
2. Hayashi M, Noguchi R, Abe M, Osaki J, Adachi Y, Iwata S, Sasaki K, Kondo T, Yoshimatsu Y. Gastric biopsy-derived cell line and its utility in assessing tumor cell drug sensitivity. Biomedical research (Tokyo, Japan), 46:27-35, 2025
3. Iwata S, Noguchi R, Oosaki J, Adachi Y, Shiota Y, Kobayashi E, Takemori T, Nishino S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-SFT1-C1: a novel patient-derived cell line of solitary fibrous tumor. Human cell, 38:49, 2025
4. Iwata S, Ono T, Noguchi R, Osaki J, Adachi Y, Shiota Y, Fukushima S, Nishino S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-dCS2-C1: a novel patient-derived cell line of dedifferentiated chondrosarcoma. Human cell, 38:78, 2025
5. Iwata S, Noguchi R, Osaki J, Adachi Y, Shiota Y, Ogura K, Nishino S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-OS2-C1: a novel patient-derived cell line of osteosarcoma. Human cell, 38:81, 2025
6. Noguchi R, Yanagihara K, Iino Y, Komatsu T, Kubo T, Ono T, Osaki J, Adachi Y, Iwata S, Shiota Y, Seyama T, Kondo T. Establishment and characterization of novel cancer cachexia-inducing cell line, Aku60GC, of scirrhous gastric cancer. Human cell, 38:82, 2025
7. Iwata S, Noguchi R, Osaki J, Adachi Y, Shiota Y, Osaki S, Nishino S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PS2-C1: a novel cell line of high-grade pleomorphic spindle cell sarcoma, most consistent with myxofibrosarcoma. Human cell, 38:93, 2025
8. Adachi Y, Noguchi R, Yoshimatsu Y, Sin Y, Osaki J, Ono T, Iwata S, Akiyama T, Tsuchiya R, Toda Y, Ishihara S, Ogura K, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1. Human cell, 37:874-885, 2024
9. Osaki J, Noguchi R, Ono T, Adachi Y, Iwata S, Toda Y, Funada T, Iwata S, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-SS6-C1: a novel patient-derived cell line of synovial sarcoma. Human cell, 37:1734-1741, 2024
10. Adachi Y, Noguchi R, Osaki J, Ono T, Iwata S, Akiyama T, Tsuchiya R, Toda Y, Tetsuya S, Iwata S, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1. Human cell, 37:1742-1750, 2024
11. Noguchi R, Osaki J, Ono T, Adachi Y, Iwata S, Yoshimatsu Y, Sasaki K, Kawai A, Kondo T. Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning. In vitro cellular & developmental biology. Animal, 60:1200-1214, 2024
12. Iwata S, Ono T, Noguchi R, Osaki J, Adachi Y, Shiota Y, Iwata S, Nishino S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-GCTB14-C1 and NCC-GCTB15-C1: two novel patient-derived cell lines of giant cell tumor of bone. Human cell, 38:20, 2024
13. Noguchi R, Ono T, Osaki J, Adachi Y, Iwata S, Shiota Y, Yanagihara K, Nishino S, Funada T, Ogura K, Yoshida A, Kawai A, Kondo T. Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1. Human cell, 38:28, 2024
14. Adachi Y, Noguchi R, Osaki J, Ono T, Akiyama T, Kondo H, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone. Human cell, 38:29, 2024
15. Jia X, Yang C, Chen L, Yu C, Kondo T. The diagnosis and treatment of the epithelioid sarcomas involving the peripheral nerves. Scientific reports, 14:31096, 2024